Showing 7501-7510 of 9070 results for "".
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- La Roche-Posay Gives Back: Brand Supports USC's Skin of Color and Pigmentary Disorders Research Fellowshiphttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-supports-uscs-skin-of-color-and-pigmentary-disorders-research-fellowship/2461558/La Roche-Posay is supporting the Skin of Color and Pigmentary Disorders Research Fellowship at the Keck School of Medicine of University of Southern California (USC). The fellowship allows students, between their third and fourth years of medical school, the opportunity to con
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- Medical Groups Offer Updated Guidance on Hand Hygiene in Healthcare Settingshttps://practicaldermatology.com/news/groups-offer-updated-guidance-on-hand-hygiene-in-healthcare-settings/2461551/Five medical organizations are recommending updated best practices for hand hygiene to protect patients and staff in healthcare settings. The new recommendations emphasize the importance of healthy skin and nails and easy access to alcohol-based hand sanitizers. Strategi
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c